Harnessing the Body’s Innate Immune System
Myeloid’s proprietary cell therapy technology has been developed by leading scientists in oncology, immunology, cell therapy, synthetic biology, and virology. We have developed a versatile and powerful platform to reprogram cells of the innate immune system. By targeting myeloid cells, our approach allows for diverse applications and the recruitment of the broader immune system. Our areas of interest include viruses, cancers, and autoimmune diseases.
Empowering Myeloid Cells to Cure Disease
Developing a Potent Anti-COVID 19 Immune Response
Robust cytotoxic T cell responses are an important part of a durable SARS-CoV-2 immune responses. Current vaccine strategies, however, are mainly focused on inducing a B cell or humoral response.
We are harnessing the unique ability of myeloid cells to mobilize the T cell or cellular immune response to recognize and kill virally infected cells. Our myeloid cell vaccine is designed to elicit potent T cell activity for long-term immunity.
Developing a Potent Cancer Immune Response
Cancer cells exploit intrinsic mechanisms that lead to its evasion of an anti-tumor speciﬁc immune response. These mechanisms enable cancer cells to proliferate abnormally and bypass surveillance by the immune system.
Myeloid cells are selectively recruited by the tumor microenvironment to promote immunosuppression, angiogenesis, and tumor cell growth. To take advantage of myeloid cell recruitment to tumors, we are engineering myeloid cells to eradicate tumors through direct anti-inflammatory activities, transformation of the tumor microenvironment and recruitment of T and NK cells. Together these activities can lead to eradication of the tumor.
Planned ATAK™ Clinical Programs
Myeloid Therapeutics is planning multiple phase I clinical trials leveraging our proprietary ATAK™ platform to address the critical global viral crisis' in addition to important cancer indications